» Articles » PMID: 34195556

Cancer Mortality Rates Increasing Vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications

Abstract

Objective: To highlight the current global trends in mortality for cardiovascular disease and cancer.

Methods: The World Health Organization and the World Bank DataBank databases were used to analyze mortality rates for cancer and cardiovascular disease by calculating age-standardized mortality rates (ASRs) from 2000 to 2015 for high-income, upper-middle-income, and lower-middle-income countries. Data for cancer mortality and population for 43 countries representing 5 of the 7 continents (except Australia and Antarctica) were analyzed.

Results: From 2000 to 2015, there was an increase in the ASR for cancer for both men and women irrespective of a country's income status, representing an overall 7% increase in cancer ASR (Pearson , +0.99; <.00001). We report a higher ASR for cancer in high-income countries than in upper-middle-income and lower-middle-income countries specifically; high-income countries saw a 3% increase in cancer ASR vs +31% for upper-middle-income and +19% for lower-middle-income countries (<.01). There has been a decrease in the ASR for cardiovascular disease for the 15 years analyzed (<.00001). In addition, high-income countries had a higher ASR for cardiovascular disease than upper-middle-income countries during the 15-year period (<.05).

Conclusion: We suspect that because of early detection and targeted interventions, cardiovascular disease mortality rates have decreased during the past decade. On the basis of our results, cancer mortality rates continue to rise, with the projection of surpassing cardiovascular disease mortality rates in the near future.

Citing Articles

A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer.

de Moraes F, Sano V, Dantas C, Hoffmeister N, Kelly F, Burbano R Clin Transl Oncol. 2024; .

PMID: 39500846 DOI: 10.1007/s12094-024-03772-2.


Health-related quality of life of cancer patients: Findings from Western Rajasthan.

Vyas P, Chugh A, Bhardwaj P, Joshi N, Vyas B, Jain Y J Family Med Prim Care. 2024; 13(9):4071-4077.

PMID: 39464968 PMC: 11504750. DOI: 10.4103/jfmpc.jfmpc_734_24.


The Role of Inhaled Chitosan-Based Nanoparticles in Lung Cancer Therapy.

Silva A, Costa M, Zacaron T, Ferreira K, Braz W, Fabri R Pharmaceutics. 2024; 16(8).

PMID: 39204314 PMC: 11359377. DOI: 10.3390/pharmaceutics16080969.


An Assessment of Behavioral Risk Factors in Oncology Patients.

Mititelu M, Licu M, Neacsu S, Calin M, Matei S, Scafa-Udriste A Nutrients. 2024; 16(15).

PMID: 39125407 PMC: 11314614. DOI: 10.3390/nu16152527.


Special Issue "Cancer Biomarker Research and Personalized Medicine 2.0".

Meehan J, Gray M J Pers Med. 2024; 14(6).

PMID: 38929770 PMC: 11204983. DOI: 10.3390/jpm14060549.


References
1.
Reddy K . Cardiovascular disease in non-Western countries. N Engl J Med. 2004; 350(24):2438-40. DOI: 10.1056/NEJMp048024. View

2.
Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre M . The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1(4):505-27. PMC: 4500822. DOI: 10.1001/jamaoncol.2015.0735. View

3.
Jonsson B, Hofmarcher T, Lindgren P, Wilking N . The cost and burden of cancer in the European Union 1995-2014. Eur J Cancer. 2016; 66:162-70. DOI: 10.1016/j.ejca.2016.06.022. View

4.
Taksler G, Rothberg M . Assessing Years of Life Lost Versus Number of Deaths in the United States, 1995-2015. Am J Public Health. 2017; 107(10):1653-1659. PMC: 5607680. DOI: 10.2105/AJPH.2017.303986. View

5.
Feigin V, Nguyen G, Cercy K, Johnson C, Alam T, Parmar P . Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. N Engl J Med. 2018; 379(25):2429-2437. PMC: 6247346. DOI: 10.1056/NEJMoa1804492. View